67 related articles for article (PubMed ID: 3897260)
1. Metabolic response to three years of continuous, basal rate intravenous insulin infusion in type II diabetic patients.
Blackshear PJ; Shulman GI; Roussell AM; Nathan DM; Minaker KL; Rowe JW; Robbins DC; Cohen AM
J Clin Endocrinol Metab; 1985 Oct; 61(4):753-60. PubMed ID: 3897260
[TBL] [Abstract][Full Text] [Related]
2. Basal-rate intravenous insulin infusion compared to conventional insulin treatment in patients with type II diabetes. A prospective crossover trial.
Blackshear PJ; Roussell AM; Cohen AM; Nathan DM
Diabetes Care; 1989; 12(7):455-63. PubMed ID: 2667926
[TBL] [Abstract][Full Text] [Related]
3. Glucose disposal in obese non-diabetic and diabetic type II patients. A study by indirect calorimetry and euglycemic insulin clamp.
Golay A; Defronzo RA; Thorin D; Jequier E; Felber JP
Diabete Metab; 1988; 14(4):443-51. PubMed ID: 3066652
[TBL] [Abstract][Full Text] [Related]
4. Naloxone effects on post-prandial glucose, insulin and C-peptide levels in obese subjects.
De Marinis L; Mancini A; De Luca AM; Fiumara C; Zuppi P; Sammartano L; Valle D
Diabetes Res; 1993; 23(2):83-91. PubMed ID: 7712683
[TBL] [Abstract][Full Text] [Related]
5. Advantageous metabolic effects of pulsatile insulin delivery in noninsulin-dependent diabetic patients.
Paolisso G; Sgambato S; Gentile S; Memoli P; Giugliano D; Varricchio M; D'Onofrio F
J Clin Endocrinol Metab; 1988 Nov; 67(5):1005-10. PubMed ID: 3053747
[TBL] [Abstract][Full Text] [Related]
6. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.
Vilsbøll T; Krarup T; Madsbad S; Holst JJ
Diabetologia; 2002 Aug; 45(8):1111-9. PubMed ID: 12189441
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects.
DeFronzo RA; Barzilai N; Simonson DC
J Clin Endocrinol Metab; 1991 Dec; 73(6):1294-301. PubMed ID: 1955512
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state.
Egan JM; Meneilly GS; Habener JF; Elahi D
J Clin Endocrinol Metab; 2002 Aug; 87(8):3768-73. PubMed ID: 12161508
[TBL] [Abstract][Full Text] [Related]
9. Continuous subcutaneous insulin infusion therapy decreases insulin resistance in type 1 diabetes.
Yki-Järvinen H; Koivisto VA
J Clin Endocrinol Metab; 1984 Apr; 58(4):659-66. PubMed ID: 6365945
[TBL] [Abstract][Full Text] [Related]
10. Effects of insulin on fasting and meal-stimulated somatostatin-like immunoreactivity in noninsulin-dependent diabetes mellitus: evidence for more than one mechanism of action.
Gutniak M; Grill V; Efendić S
J Clin Endocrinol Metab; 1986 Jan; 62(1):77-83. PubMed ID: 2866196
[TBL] [Abstract][Full Text] [Related]
11. Dissociation between fat-induced in vivo insulin resistance and proximal insulin signaling in skeletal muscle in men at risk for type 2 diabetes.
Storgaard H; Jensen CB; Björnholm M; Song XM; Madsbad S; Zierath JR; Vaag AA
J Clin Endocrinol Metab; 2004 Mar; 89(3):1301-11. PubMed ID: 15001626
[TBL] [Abstract][Full Text] [Related]
12. Continuous subcutaneous insulin infusion fails to correct impaired basal glucose metabolism and impaired insulin sensitivity of adipocytes from patients with type 1 (insulin-dependent) diabetes.
Pedersen O; Hjøllund E; Beck-Nielsen H; Richelsen B; Sørensen NS
Diabetes Res; 1986 Jan; 3(1):17-23. PubMed ID: 3514067
[TBL] [Abstract][Full Text] [Related]
13. Comparison of porcine insulin and human insulin (Novo) using the glucose-controlled insulin infusion system, glucose-insulin dose-response curves, and the outpatient effectiveness of human insulin (Novo) in insulin-dependent diabetes.
Charles MA; Szekeres A; Staten M; Worcester B; Walsh KM
Diabetes Care; 1983; 6 Suppl 1():29-34. PubMed ID: 6343034
[TBL] [Abstract][Full Text] [Related]
14. A simple insulin infusion algorithm for establishing and maintaining overnight near-normoglycemia in type I and type II diabetes.
Mokan M; Gerich JE
J Clin Endocrinol Metab; 1992 Apr; 74(4):943-5. PubMed ID: 1548362
[TBL] [Abstract][Full Text] [Related]
15. Safety of continuous subcutaneous insulin infusion: metabolic deterioration and glycaemic autoregulation after deliberate cessation of infusion.
Pickup JC; Viberti GC; Bilous RW; Keen H; Alberti KG; Home PD; Binder C
Diabetologia; 1982 Mar; 22(3):175-9. PubMed ID: 7042428
[TBL] [Abstract][Full Text] [Related]
16. Five-day programmed intraperitoneal insulin delivery in insulin-dependent diabetic man.
Schade DS; Eaton RP; Friedman NM; Spencer WJ; Standefer JC
J Clin Endocrinol Metab; 1981 Jun; 52(6):1165-70. PubMed ID: 7014596
[TBL] [Abstract][Full Text] [Related]
17. Control of blood glucose in experimental diabetes by means of a totally implantable insulin infusion device.
Blackshear PJ; Rohde TD; Grotting JC; Dorman FD; Perkins PR; Varco RL; Buchwald H
Diabetes; 1979 Jul; 28(7):634-9. PubMed ID: 446920
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of continuous subcutaneous insulin infusion.
Lauritzen T; Pramming S; Deckert T; Binder C
Diabetologia; 1983 May; 24(5):326-9. PubMed ID: 6347780
[TBL] [Abstract][Full Text] [Related]
19. Glycerol-insulin raises circulating insulin antibodies in type I diabetic patients treated with permanently implanted devices.
Micossi P; Galimberti G; Librenti MC; Petrella G; Dozio N; Cristallo M; Sodoyez JC; Sodoyez-Goffaux F; Grau U; Zoltobrocki M
Metabolism; 1988 Nov; 37(11):1029-32. PubMed ID: 3054429
[TBL] [Abstract][Full Text] [Related]
20. Maintenance of basal plasma glucose and insulin concentrations in maturity-onset diabetes.
Holman RR; Turner RC
Diabetes; 1979 Mar; 28(3):227-30. PubMed ID: 446907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
